| European Case Law Identifier: | ECLI:EP:BA:2014:R001013.20140210 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 10 February 2014 | ||||||||
| Case number: | R 0010/13 | ||||||||
| Petition for review of: | T 1760/11 | ||||||||
| Application number: | 00108480.5 | ||||||||
| IPC class: | C07D 401/12 A61K 31/44 A61P 1/04 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Magnesium salt of the (-)-enantiomer of omeprazole and its use | ||||||||
| Applicant name: | AstraZeneca AB | ||||||||
| Opponent name: | Hexal AG Teva Pharmaceutical Industries Ltd. Mepha AG STADA Arzneimittel AG Pinewood Laboratories Limited ETHYPHARM Actavis Group hf. Lupin Limited Zentiva a.s. Generics [UK] Limited Ratiopharm GmbH 1A Pharma GmbH / Hexal Pharma GmbH Hörnchen, Ulrich, Dr. |
||||||||
| Board: | EBA | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Fundamental violation of the right to be heard (no) Clearly inadmissible Clearly unallowable List of grounds exhaustive Obligation to raise objection Sufficiently reasoned (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/r130010eu1.html
Date retrieved: 17 May 2021